TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02866838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: intravenous
Study: NCT03217929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-taVNS
Description: Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
Study: NCT03126266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: re-irradiation
Description: if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
Study: NCT00705172

Intervention type: DRUG
Intervention: somatropin
Description: Prader-Willi syndrome children treated with at least one dose of Norditropin®
Study: NCT01841723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study: NCT02309541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: feedback canceller algorithm (Firmware)
Description: The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: feedback canceller algorithm (Firmware)
Description: The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
Study: NCT02503696

Intervention type: DEVICE
Intervention: Stool Collection Kit
Description: Stool Collection Kit.
Study: NCT03906929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: buried intramedullary K-wire
Description: Using of buried kirschner wire in pediatric forearm fixation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exposed intramedullary K-wire
Description: Using of exposed kirschner wire in pediatric forearm fixation
Study: NCT02780115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
Study: NCT02735759

Intervention type: DEVICE
Group type: OTHER
Intervention: Photoacoustic flow cytometry device
Description: The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.

Intervention type: DEVICE
Group type: OTHER
Intervention: Photoacoustic flow cytometry device
Description: The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
Study: NCT01153815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1358820(Botulinum toxin type A)
Description: GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04105673

Intervention type: OTHER
Intervention: Clinical examination and survey
Description: Children will be seen during an one consultation. A clinical examination and survey are realized.
Study: NCT00711295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
Study: NCT02780115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: Vehicle to AGN-199201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: Vehicle to AGN-199201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 Vehicle
Description: Vehicle to AGN-190584
Study: NCT00711295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
Study: NCT01841723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT02029911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study: NCT02780115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 Vehicle
Description: Vehicle to AGN-190584
Study: NCT03891602

Intervention type: BEHAVIORAL
Intervention: Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)
Description: Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.

Intervention type: BEHAVIORAL
Intervention: Patient Trust in the Medical
Description: Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84.

Intervention type: BEHAVIORAL
Intervention: Decision Conflict Scale (DCS) - Lung Cancer Screening
Description: The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict.

Intervention type: BEHAVIORAL
Intervention: Shared Decision Making Questionnaire (SDM-Q)- Patient
Description: Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94.

Intervention type: BEHAVIORAL
Intervention: Stage of Readiness for Smoking Cessation - Contemplation Ladder
Description: Among current smokers

Intervention type: BEHAVIORAL
Intervention: Primary Care Clinicians' Lung Cancer Screening Survey
Description: Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
Study: NCT04656249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
Study: NCT01659762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stromal cell
Study: NCT05935449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Lidocaine
Description: Dermal filler injection to facial areas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Formaderm Dermal Filler Injection
Description: Dermal filler injection to facial areas
Study: NCT00658203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Living CHF
Description: PEA CRT optimization

Intervention type: DEVICE
Group type: OTHER
Intervention: New Living CHF
Description: Standard optimized CRT.
Study: NCT02787148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study: NCT03299088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT03588312

Intervention type: PROCEDURE
Intervention: Aortoplasty using autologous pericardial patch
Description: hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.

Intervention type: PROCEDURE
Intervention: Aortoplasty using autologous pericardial patch
Description: hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
Study: NCT02158949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mROAD
Study: NCT01977131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cells
Study: NCT02351050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonolysis
Description: continual transcranial Doppler monitoring of middle cerebral artery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: sham transcranial Doppler monitoring of middle cerebral artery
Study: NCT00461591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study: NCT03726242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
Study: NCT02043626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DISTRICT WELLNESS COMMITTEE
Description: Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS
Description: Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS
Description: Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
Study: NCT00711295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
Study: NCT01071915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
Study: NCT03365362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Term Varenicline
Description: Varenicline tablet x 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-Term Varenicline
Description: varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy
Description: Varenicline doses are administered by opioid treatment program nurses

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Administered Therapy
Description: Varenicline doses are self-administered
Study: NCT03431714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate amodiaquine
Description: Drugs were administered under observation of the study nurse for three days
Study: NCT03845686

Intervention type: DIAGNOSTIC_TEST
Intervention: Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Description: The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Description: The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
Study: NCT01288807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipram
Description: Titration to 200mg PO daily
Study: NCT00711243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
Study: NCT02052752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Benzoyl Peroxide
Description: Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Benzoyl Peroxide Placebo
Description: The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neutrogena Rapid Clear®
Description: A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study: NCT02257229

Intervention type: PROCEDURE
Intervention: Surgical
Description: Surgery only

Intervention type: PROCEDURE
Intervention: Non-Surgical
Description: non-surgical methods such as, casting, bracing, physical therapy, and other.

Intervention type: PROCEDURE
Intervention: Non-surgical + surgical
Description: Combination of non-surgical methods subsequently followed by surgery
Study: NCT03558919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG